| abstract |
Methods of treating drug-resistant retroviral infections, such as those caused by drug- resistant HIV-I, HIV-II, and HIV-III, are disclosed. The methods involve administering a compound that is an inhibitor of retroviral propagation. The inhibitors inhibits the ability of any portion of the HIV genome involved in reverse transcription to bind to or associate with a host cell tRNA, or the inhibitor disrupts the RNA/RNA complex formed between the viral genome and the human tRNA primer, or the binding or association of the host cell tRNA to a retroviral genome initiates, primes, or facilitates reverse transcription of the retroviral genome in the absence of the administered compound. |